The Feasibility of Discontinuing Lamivudine in Lamivudine-Resistant Chronic Hepatitis B Patients on Lamivudine and Adefovir Combination Therapy

Publisher： Karger

E-ISSN： 1423-0100|57|6|337-343

ISSN： 0300-5526

Source： Intervirology, Vol.57, Iss.6, 2014-09, pp. : 337-343

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adefovir and Lamivudine Combination Therapy in Patients with Entecavir-Resistant Chronic Hepatitis B: Antiviral Responses and Evolution of Mutations

By  

Intervirology, Vol. 57, Iss. 5, 2014-06 ,pp. : 239-247

Karger

Access to resources Recommend Favorite

Virological Response and Hepatocarcinogenesis in Lamivudine-Resistant Hepatitis B Virus Genotype C Patients Treated with Lamivudine plus Adefovir Dipivoxil

By  

Intervirology, Vol. 51, Iss. 6, 2009-02 ,pp. : 385-393

Karger

Access to resources Recommend Favorite

Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance

By  

Intervirology, Vol. 57, Iss. 1, 2013-08 ,pp. : 8-16

Karger

Access to resources Recommend Favorite

Continued Lamivudine Therapy in Patients with Chronic Hepatitis B

By  

Intervirology, Vol. 46, Iss. 6, 2003-12 ,pp. : 377-387

Karger

Access to resources Recommend Favorite

Response to Adefovir Depends on Mutation Patterns in Precore Region, Basal Core Promoter and Reverse Transcriptase, and On-Treatment Responses in Lamivudine-Resistant Chronic Hepatitis B Patients

By  

Intervirology, Vol. 53, Iss. 4, 2010-03 ,pp. : 203-210

Karger

Access to resources Recommend Favorite